NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Allogene Therapeutics, Inc. ALLO
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.87
Dividend / sh · FY25
$0.00
Payout · FY25
—
ROE · FY25
-53.4%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 8-year series below
Revenue
Net income
Per share
USD -0.87
Diluted EPS, FY2025
EPS
Dividend
The company pays no cash dividend.
Profitability
-53.4%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-39.6%
Each USD of equity lost 53 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.23B
Shares outstanding, FY2025
Change, 5 years+63.3%
Change, 10 years—
The share count grew 63% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 415.9M
total assets, end of FY2025
Total assetsUSD 415.9M
EquityUSD 292.5M
CashUSD 51.7M
Current ratio7.93×
Equity funds 70% of total assets.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.0
0.0
0.0
0.0
0.1
0.0
0.0
·
Operating income $B
−0.2
−0.3
−0.3
−0.3
−0.2
−0.3
−0.2
−0.2
EBITDA $B
−0.2
−0.3
−0.3
−0.3
−0.2
−0.3
−0.2
−0.2
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.2
−0.3
−0.3
−0.3
−0.2
−0.3
−0.2
−0.2
EPS, diluted $
−0.87
−1.32
−2.09
−2.38
−1.34
−2.63
−1.83
−7.31
Dividend / sh $
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Payout %
·
·
·
·
·
·
·
·
ROE %
−53.4
−55.1
−55.5
−42.8
−18.8
−38.5
−27.7
−30.1
Shares out B
0.23
0.21
0.17
0.14
0.14
0.14
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed